Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment Abciximab (c7E3 Fab) during percutaneous coronary revascularization

A. Michael Lincoff, James E. Tcheng, Robert M. Califf, Theodore Bass, Jeffrey J. Popma, Paul S. Teirstein, Neal S. Kleiman, Larry J. Hattel, H. Vernon Anderson, James J. Ferguson, Catherine F. Cabot, Keaven M. Anderson, Lisa G. Berdan, Maura H. Musco, Harlan F. Weisman, Eric J. Topol

Research output: Contribution to journalArticlepeer-review

129 Scopus citations

Fingerprint

Dive into the research topics of 'Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment Abciximab (c7E3 Fab) during percutaneous coronary revascularization'. Together they form a unique fingerprint.

Medicine & Life Sciences